enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Niraparib/abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Niraparib/abiraterone_acetate

   Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib , a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate , a CYP17 inhibitor (hormone antagonist).

3. Abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Abiraterone_acetate

   Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [2] [6] [5] [4] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.

4. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

5. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]

6. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   [78] [79] [80] Of the SAAs, CPA is the only one that has been widely used in the treatment of prostate cancer. [28]: 488 As antiandrogens, the SAAs have largely been replaced by the NSAAs and are now rarely used in the treatment of prostate cancer, due to the superior selectivity, efficacy, and tolerability profiles of NSAAs.

7. Galeterone - Wikipedia

   en.wikipedia.org/wiki/Galeterone

   Galeterone (developmental code names TOK-001, VN/124-1) is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. [1] It possesses a unique triple mechanism of action , acting as an androgen receptor antagonist , androgen receptor down regulator, [ 2 ] and CYP17A1 inhibitor , [ 3 ...